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Abstract
Background: High-grade gliomas have poor prognosis, requiring aggressive treatment. The aim of this study is to 
explore mitotic and centrosomal dysregulation in gliomas, which may provide novel targets for treatment.
Methods: A case-control study was performed using 34 resected gliomas, which were separated into low- and high-
grade groups. Normal human brain tissue was used as a control. Using immunohistochemical analysis, 
immunofluorescent microscopy, and RT-PCR, detection of centrins 1 and 2, γ-tubulin, hNinein, Aurora A, and Aurora B, 
expression was performed. Analysis of the GBM8401 glioma cell line was also undertaken to complement the in vivo 
studies.
Results: In high-grade gliomas, the cells had greater than two very brightly staining centrioles within large, atypical 
nuclei, and moderate-to-strong Aurora A staining. Comparing with normal human brain tissue, most of the mRNAs 
expression in gliomas for centrosomal structural proteins, including centrin 3, γ-tubulin, and hNinein isoforms 1, 2, 5 
and 6, Aurora A and Aurora B were elevated. The significant different expression was observed between high- and low-
grade glioma in both γ-tubulin and Aurora A mRNA s. In the high-grade glioma group, 78.6% of the samples had higher 
than normal expression of γ-tubulin mRNA, which was significantly higher than in the low-grade glioma group (18.2%, 
p < 0.05).
Conclusions: Markers for mitotic dysregulation, such as supernumerary centrosomes and altered expression of 
centrosome-related mRNA and proteins were more frequently detected in higher grade gliomas. Therefore, these 
results are clinically useful for glioma staging as well as the development of novel treatments strategies.
Background
Gliomas are common brain cancers that are notoriously
hard to treat. High-grade gliomas are especially difficult,
and their prognosis is poor. Standard treatment for high-
grade gliomas is limited to resection followed by radio/
chemotherapy, resulting in a median survival of 14
months [1]. Therefore, the development of novel, tar-
geted therapies is the best hope for glioma patients.
In recent years, rapid advances in understanding the
role of mitotic dysregulation as a key oncogenic event
have been reported. A number of cell cycle checkpoints
exist at the mitosis phase of the cell cycle to ensure that
chromosome segregation occurs in a timely and orderly
fashion and that the correct number of centrioles and
chromosomes are segregated into the two daughter cells
[2]. If mitosis becomes dysregulated in a cell often due to
centrosome abnormalities, aneuploidy may result, which
may contribute to cellular transformation [2]. Although it
is unknown whether centrosome abnormalities induce
cellular transformation or result as a consequence of it,
detection of centrosome defects in early-stage cancers
supports the notion that they may directly contribute to
transformation [2].
Increased knowledge of mitotic regulation in normal
and cancerous cells has resulted in the development of
drugs against these new targets [3,4]. A number of
mitotic regulatory proteins, including Checkpoint with
forkhead and ring finger domains (CHFR), Aurora A (also
known as serine/threonine kinase 15 [STK15]), Aurora B,
Aurora C, Polo-like kinases (Plk1-4), and Nek kinases
(NIMA1-11) [5,6] as well as structural proteins of the
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centrosome, such as γ-tubulin, centrin 2, centrin 3, peri-
centrin, and hNinein have been identified [2,7,8].
Although genetic and epigenetic changes that result in
mitotic dysregulation have been identified in various can-
cer cells [2], few studies have assessed it in gliomas [9-14].
Recently, a large genome-wide association study (GWAS)
of 1,878 glioma cases versus 3,670 controls was under-
taken [15,16]. Five critical susceptibility loci for glioma
were identified, one of which was 20q13.33 [17], which is
very near the locus for STK15/Aurora A located at
20q13.2-q13.3 http://www.ncbi.nlm.nih.gov/gene/
6790?ordinalpos=5&itool=EntrezSystem2.PEn-
trez.Gene.Gene_ResultsPanel.Gene_RVDocSum. Fur-
ther analysis of 692 high-grade gliomas versus 3,992
controls in the GWAS identified the RTEL gene, which is
involved in regulation of homologous recombination, as a
putative gene at the 20q13.33 locus associated with high-
grade gliomas rather than Aurora A [16]. Although these
data serve to reinforce the importance of this region of
the genome and the potential association of Aurora A
with high-grade glioma, the inconsistent results from var-
ious groups are a reminder that this research is at the
early stages. In other cancer types, data is accumulating
that Aurora A is a good prognostic indicator [16-19].
Other centrosomal structural proteins, such as hNi-
nein, centrin, and pericentrin, may influence spindle
body assembly during mitosis and are overexpressed in
malignant tumors [7,8,20]. For example, Pihan et al. [21]
selectively induced centrosome abnormalities by elevat-
ing pericentrin levels in prostate epithelial cell lines,
which replicated many phenotypic characteristics associ-
ated with tumor-like prostate carcinoma. Pericentrin and
γ-tubulin assemble into a unique centrosome lattice,
which acts as a higher order organization of microtubule
nucleating sites at the centrosome [22].
To test the hypothesis that altered expression of cen-
trosome-related proteins may contribute to glioma grade,
we analyzed the expression levels of centrosome regula-
tory proteins, such as Aurora A, and the chromosomal
passenger protein, Aurora B, as well as centrosome struc-
tural proteins, including centrins 1 and 2, γ-tubulin, and
hNinein in 34 glioma samples. In addition, high- and low-
grade gliomas were compared to identify specific altera-
tions that may facilitate glioma staging as well as provide
novel targets for treatment. Finally, the glioma cell line,
GBM8401, was also analyzed for centrosome defects.
Methods
Tissue collection
Brain tumor samples were obtained from patients under-
going surgery or biopsy at either the Kaohsiung Medical
University Hospital or the Chi-Mei Medical Center in
Taiwan. The tumors were classified according to the 1993
WHO classification [23]. Normal human brain tissues
were purchased from Clontech laboratories (Mountain
View, CA); the tissues were isolated from 8 male Cauca-
sians (ages 43-65). Glioma tissue samples were collected
fresh at the time of surgery, snap frozen in liquid nitro-
gen, and stored frozen at -135°C. The presence of cancer
tissue and histological grade was confirmed by a trained
pathologist.
This study used only excess tissue from medically-nec-
essary surgeries and excess diagnostic samples; it was
approved by the Institutional Review Board of the
Chung-Ho Memorial Hospital, Kaohsiung Medical Uni-
versity (KMUH-IRB-960237 and KMUH-IRB-960435). In
addition, written informed consent was obtained from all
patients. This study was done in accordance with the
principles outlined in the Declaration of Helsinki.
RNA isolation
RNA was isolated with TRIzol reagent (Gibco-BRL,
Rockville, MD) following the manufacturer's instructions.
Briefly, 100 mg of tissue was homogenized in 1 mL of
TRIzol reagent and mixed with 0.2 mL of guanidinium
phenol/chloroform. After centrifugation (12,000 × g, 15
min, 4°C), RNA was recovered from the aqueous layer by
precipitation with isopropyl alcohol. After the RNA was
washed in 75% ethanol, it was air-dried and resuspended
in DEPC-treated water.
RT-PCR analysis
Reverse transcriptase PCR was performed following stan-
dard protocols. To generate cDNA, 5 μg RNA was incu-
bated in a reaction mixture containing 50 mM Tris-HCl
(pH 8.3), 10 mM DTT, 10 mM KCl, 0.5 mM dNTPs, 30 μg
RNAsin (Promega, Madison, WI), 0.8 units of Super-
script II reverse transcriptase (Gibco-BRL), and water to
20 μL for 1 h at 37°C.
The PCR reactions consisted of 2 μL of cDNA in a 50
μL reaction containing 50 mM Tris-HCl (pH 9.2), 16 mM
(NH4)2SO4, 1.75 mM MgCl2, 10% DMSO, 0.3 mM of each
primer, and 5 units of Pwo DNA polymerase (Boehringer
Mannheim, Mannheim, Germany). The PCR conditions
included denaturation at 95°C for 1 min followed by 30
cycles of 95°C for 30 sec, 58°C for 60 sec, and 68°C for 25
sec and one final extension at 68°C for 10 min. The fol-
lowing PCR primer sets were used:
γ-tubulin: forward, 5' CTCAAGAGGCTGACGCA-
GAAT 3' and reverse, 5' CTGGCTGACATGATGGTA-
GACAC 3'; centrin 2: forward, 5' CGGGAAGCTTT
TGATCTTTTCGATGCG 3' and reverse, 5' GCTG-
GTCTTTTTCATGATGCG 3'; centrin 3: forward, 5'
TTAAATGTCACCAGTCATAATAGC 3' and reverse, 5'
AATGAGTTTAGCTCTGAGAAGT 3'; Aurora A: for-
ward 5' GCTGGAGAGCTTAAAATTGCAG 3' and
reverse, 5' TTTTGTAGGTCTCTTGGTATGTG 3';
Aurora B: forward, 5' ATGGCCCAGAAGGAGAACTC-Loh et al. BMC Cancer 2010, 10:268
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CTAC 3' and reverse, 5' GTAGAGACGCAGGATGTTG-
GGATG 3'; and α-actin: forward, 5'
AGCGGGAAATCGTGCGTG 3' and reverse, 5' CAG-
GGTACATGGTGGTGC 3'. To amplify the 4 alterna-
tively spliced forms of the C-terminal region of hNinein,
we used primer combinations that included the hNinein
forward primer, 5' CAGCTGCTTTGGCAAGA-
GAATGA 3', and reverse primers for isoform 1, 5' TCA-
CAGGTGCCCAATCCTTCTG 3', isoform 2, 5' CTAT
GACCTCAAAGGAGGTGTAG 3', isoform 5, 5' TTAAT-
GGCAATAAAGGGATGTAAA 3', and isoform 6, 5'
CTACTTCCAACCACTGAGTT 3'.
The expression level was estimated by densitometer,
+++ abundant; ++ moderate; + rare; - absent.
Immunohistochemistry
Frozen tissue samples were cryosectioned, fixed with ace-
tone at room temperature for 40 minutes, and incubated
with monoclonal antibodies specific for Aurora A (GTU-
88; Sigma, St. Louis, MO). Aurora A expression was then
visualized using the alkaline phosphatase anti-alkaline
phosphatase method [24].
Confocal microscopy
Antibodies specific for γ-tubulin (Sigma), hNinein (pAb)
(our preparation, rabbit, hNinein 1617_1931 a.a.), and
Aurora A (pAb) (Sigma) were diluted in PBS containing
1% bovine serum albumin. Fluorescent secondary anti-
bodies were diluted 1:200 in PBS with 1% BSA and 5%
goat normal serum.
GBM8401 glioma cells [25] were purchased from
American Type Culture Collection (ATCC, Manassas,
V A) and cultured on glass coverslips in RPMI medium
(Gibco) supplemented with 10% fetal bovine serum, 1%
nonessential amino acids (Gibco), 100 IU/ml penicillin,
and 100 μg/ml streptomycin (Gibco) at 37°C in a humidi-
fied 5% CO2 incubator for 24 hr. For synchronization,
cells were treated with 200 ng/ml nocodazadole (Sigma).
The coverslips were then washed twice with PBS, fixed
w i t h  i c e - c o l d  m e t h a n o l  f o r  4  m i n  a t  4 ° C ,  a n d  w a s h e d
twice with PBS. For immunofluorescence of glioma tis-
sues, frozen sections were prepared as above.
The coverslips with glioma cells or slides with histology
sections were then incubated with primary antibody for 1
h at room temperature and washed twice in PBS for 5
min. After incubation at room temperature for 30 min
with a fluorescent (Texas red or fluorescein isothiocya-
nate)-conjugated secondary antibody (Invitrogen) and
DAPI (Roche) staining, the specimens were washed twice
in PBS for 5 min. The coverslips were then dried and
mounted onto glass slides, and the slides were observed
by confocal microscopy (PM-20 camera; Olympus,
Tokyo, Japan; MRC-1024 laser confocal system; Bio-Rad,
Hercules, CA).
Statistical analysis
Categorical variables, including four-level expressions
and two-level expressions compared to normal brain tis-
sue, were presented as counts and percentages. Fisher's
exact test was performed to test the independence
between the categorical variables and the two groups:
high- and low-grade gliomas. A p-value < 0.05 was con-
sidered statistically significant. Statistical analyses were
performed using SPSS 15.0 statistical software (SPSS Inc.,
Chicago, IL).
Results
Using confocal microscopy to visualize γ-tubulin, a major
structural protein of the centrosome, multiple cen-
trosomes were observed in GBM8401 cells (Fig. 1). Nota-
bly, the centrosome number was not consistent from cell
to cell, reflecting multiple genetic clones within the cell
line and/or an inability of the glioma cells to regulate cen-
trosome number. In synchronized GBM4801 glioma cells,
multiple centrosomes were observed in 20% of the syn-
chronized cells (Fig. 1B). When the GBM8401 cells were
originally described, the cell line had a near-diploid 48,
XX karyotype [25].
Centrosomes were visualized in the glioma samples
using confocal microscopy of tissue sections to visualize
γ-tubulin and hNinein expression (Fig. 2B). In low-grade
gliomas, the two centrioles of the centrosome were faintly
visible and the nuclei were morphologically normal (Fig.
2B, upper panels). In contrast, high-grade gliomas had
greater than two, often very brightly staining centrioles
within large, atypical nuclei (Fig. 2B, lower panels). These
enlarged nuclei with multiple centrioles were seen in the
glioma cell line (Fig. 1B).
Immunohistochemical analysis of Aurora A in the
glioma samples revealed little-or-no expression in low-
grade gliomas (Fig. 2A, upper panel); however, moderate-
to-strong Aurora A staining in the high-grade gliomas
was observed (Fig. 2A, lower panel). The presence of high
Figure 1 Centrosome defects in the glioma cell line, GBM8401. 
Centrosomes were visualized with antibodies specific for γ-tubulin 
(green). DNA was stained with DAPI (blue). Bar: 10 μm, magnification 
2000 ×. A, Bipolar spindles. B, Multipolar spindles.Loh et al. BMC Cancer 2010, 10:268
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Aurora A expression levels corresponded with the
nuclear and centrosomal abnormalities in the high-grade
gliomas.
Having established that the level of Aurora A, a mitotic
regulatory protein, and centrosome abnormalities, which
are affected by Aurora A, were elevated in high- but not
low-grade gliomas, we used RT-PCR to analyze the
mRNA expression levels of a panel of regulatory and
structural proteins of centrosomes (Fig. 3). In normal
human brain tissue, the mRNA expression levels for cen-
trosomal structural proteins, including centrin 3, γ-tubu-
lin, and hNinein isoforms 1, 2, 5 and 6, was low; there was
no detectable expression of Aurora A and Aurora B
mRNA. In gliomas, most of the mRNAs analyzed in the
panel were elevated to varying degrees (Fig. 3).
In order to identify mRNAs common to all high-grade
gliomas, tissue from a total of 34 glioma patients was col-
lected and divided into high-grade (n = 23) and low-grade
glioma (n = 11) groups, according to the WHO guideline
[23]. In addition to analyzing the glioma specimens, the
expression profiles were also analyzed in normal brain
tissue, and were characterized as absent (-), rare (+),
moderate (++), and abundant (+++), according to the
expression intensities. In normal brain tissue, expression
of hNinein isoforms 1, 2, 5, and 6, γ-tubulin, and centrin 3
was rare whereas Aurora A, Aurora B, and centrin 2
mRNA expression was absent (data not shown). As
shown in Table 1, significant different expression were
observed between high- and low-grade glioma in both γ-
tubulin and Aurora A mRNA s. Specifically, in low-grade
glioma group, γ-tubulin expression was rare in 81.8% (9/
11) and moderate in 18.2% (2/11) of the samples. How-
ever, in the high-grade glioma group, 60.9% (14/23) and
14.4% (4/23) displayed moderate and abundant γ-tubulin
expression, respectively. In addition, in the low-grade
glioma group, Aurora A expression was absent in 21.3%
(3/11) of the samples and rare in 72.7% (8/11); however,
in the high-grade group, no sample showed absent of
Aurora A expression, and its expression was rare in 87%
(20/23) and moderate in 13.0% (3/23) of the samples.
As shown in Table 2, the mRNA expression levels of
structural and regulatory centrosomal proteins in low-
and high-grade gliomas were compared relative to levels
observed in normal brain tissue. The mRNA expression
levels were divided into two groups, "normal" and "higher
Figure 3 RT-PCR analysis of hNinein isoforms 5 and 6, γ-tubulin, 
Aurora A, and Aurora B in gliomas. α-tubulin expression was used as 
an internal loading control. Data from three gliomas are shown com-
pared to a normal human brain sample. Data shown are representative 
of at least three independent experiments per glioma.
Figure 2 Aurora A, hNinein, and γ-tubulin expression in low- versus high-grade glioma. A, Immunohistochemical analysis of Aurora A expres-
sion (brown), 200× magnification. B, hNinein (green) and γ-tubulin (red), counterstained for DNA with DAPI (blue) was assessed by confocal micros-
copy. Bars = 10 μm, 1000× magnification.Loh et al. BMC Cancer 2010, 10:268
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Table 1: Predictive value of relative mRNA expression levels for identifying high-grade gliomas
Group
mRNA Low-grade glioma (n = 11) High-grade glioma (n = 23) p-value
hNinein isoform 1 Absent 0 (0%) 1 (4.3%) 0.741
Rare 9 (81.8%) 13 (56.5%)
M o d e r a t e 2( 1 8 . 2 % )8( 3 4 . 8 % )
Abundant 0 (0%) 1 (4.3%)
hNinein isoform 2 Absent 2 (18.2%) 0 (0%) 0.254
Rare 7 (63.6%) 18 (78.3%)
M o d e r a t e 2( 1 8 . 2 % )4( 1 7 . 4 % )
Abundant 0 (0%) 1 (4.3%)
hNinein isoform 5 Absent 1 (9.1%) 0 (0%) 0.501
Rare 8 (72.7%) 15 (65.2%)
M o d e r a t e 2( 1 8 . 2 % )7( 3 0 . 4 % )
Abundant 0 (0%) 1 (4.3%)
hNinein isoform 6 Absent 3 (27.3%) 14 (60.9%) 0.141
R a r e 8( 7 2 . 7 % )9( 3 9 . 1 % )
Moderate 0 (0%) 0 (0%)
Abundant 0 (0%) 0 (0%)
γ-tubulin Absent 0 (0%) 0 (0%) 0.005*
R a r e 9( 8 1 . 8 % )5( 2 1 . 7 % )
Moderate 2 (18.2%) 14 (60.9%)
Abundant 0 (0%) 4 (17.4%)
Aurora A Absent 3 (27.3%) 0 (0%) 0.030*
Rare 8 (72.7%) 20 (87.0%)
Moderate 0 (0%) 3 (13.0%)
Abundant 0 (0%) 0 (0%)
Aurora B Absent 3 (27.3%) 4 (17.4%) 0.653
Rare 6 (54.5%) 16 (69.6%)
M o d e r a t e 2( 1 8 . 2 % )3( 1 3 . 0 % )
Abundant 0 (0%) 0 (0%)
Centrin 2 Absent 2 (18.2%) 1 (4.3%) 0.235
R a r e 2( 1 8 . 2 % )6( 2 6 . 1 % )
Moderate 5 (45.5%) 15 (65.2%)
Abundant 2 (18.2%) 1 (4.3%)
Centrin 3 Absent 1 (9.1%) 1 (4.3%) 0.536
R a r e 3( 2 7 . 3 % )3( 1 3 . 0 % )
M o d e r a t e 3( 2 7 . 3 % )5( 2 1 . 7 % )
Abundant 4 (36.4%) 14 (60.9%)
NOTE: In normal brain tissue Aurora A, Aurora B, and Centrin 2 mRNAs were absent and hNinein isoforms 1, 2, 5, and 6, γ-tubulin, and Centrin 
3 mRNAs were rare.
* P < 0.05 by Fisher's exact testLoh et al. BMC Cancer 2010, 10:268
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than normal", based upon its expression relative to that
observed in normal human brain tissue. In the high-grade
glioma group, 78.6% (18/23) of the samples had higher
than normal expression of γ-tubulin mRNA, which was
significantly higher than in the low-grade glioma group
(18.2%, 2/11, p < 0.05).
Discussion
To determine if centrosome-related protein expression
was altered in gliomas and if it corresponded with gliomal
staging, 34 glioma patient samples as well as GBM8401
cells were analyzed. Supernumerary centrosomes and
abnormal nuclei were detected in GBM8401 cells and in
high- but not low-grade gliomas. Elevated Aurora A
expression was also observed specifically in high-grade
gliomas. In addition, increased hNinein isoform5, hNi-
nein isoform 6, γ-tubulin, Aurora A, and Aurora B mRNA
expression was observed in gliomas as compared to nor-
mal brain. Finally, γ-tubulin and Aurora A mRNA levels
significantly increased with glioma grade.
Over 100 years ago, researchers proposed the idea that
supernumerary centrosomes could lead to abnormal
chromosome segregation and cancer [26]. In 1982, Fried-
lander used electron microscopy to explore this possibil-
ity in gliomas; however, few supernumerary centrioles
were observed, although clusters of centrioles were occa-
sionally observed [27]. Using antibodies specific to cen-
trosome proteins, we frequently observed supernumerary
centrosomes in the giant nuclei of high-grade glioma
samples and in GBM8401 cells, which is in agreement
with similar studies in other cancer types [2,28].
RT-PCR analysis of centrosomal protein expression
revealed varying degrees of upregulated expression as
compared to normal brain tissue. Each glioma may have
acquired different types of genetic (or epigenetic) changes
that were all related to the same selective pressure to alter
mitotic regulation.
Although different RNA profiles were observed for
each glioma analyzed, our theory--that there is a single
underlying trait that is being selectively altered-- suggests
that the expression of certain key proteins would be
altered in all high-grade gliomas because their upregula-
tion is a necessary consequence of removing the mitotic
checkpoints. Therefore, we analyzed the raw data to iden-
t i f y  R N A s  t h a t  w e r e  s i g n i f i c a n t l y  e l e v a t e d  i n  a l l  t h e
glioma samples, presuming these to code for key pro-
Table 2: Predictive value of abnormal mRNA levels for identifying high-grade glioma
Group
mRNA Low-grade glioma (n = 11) High-grade glioma (n = 23) p-value
hNinein isoform 1 >Normal 2 (18.2%) 9 (39.1%) 0.274
Normal 9 (81.8%) 14 (60.9%)
hNinein isoform 2 >Normal 2 (18.2%) 5 (21.7%) 1.000
Normal 9 (81.8%) 18 (78.3%)
hNinein isoform 5 >Normal 2 (18.2%) 8 (34.8%) 0.438
Normal 9 (81.8%) 15 (65.2%)
hNinein isoform 6 <Normal 3 (27.3%) 14 (60.9%) *
Normal 8 (72.7%) 9 (39.1%)
γ-tubulin >Normal 2 (18.2%) 18 (78.3%) 0.002†
Normal 9 (81.8%) 5 (21.7%)
Aurora A >Normal 0 (0%) 3 (13.0%) 0.535
Normal 11 (100.0%) 20 (87.0%)
Aurora B >Normal 2 (18.2%) 3 (13.0%) 1.000
Normal 9 (81.8%) 20 (87.0%)
Centrin 2 >Normal 7 (63.6%) 16 (69.6%) 1.000
Normal 4 (36.4%) 7 (30.4%)
Centrin 3 >Normal 7 (63.6%) 19 (82.6%) 0.388
Normal 4 (36.4%) 4 (17.4%)
NOTE: "Normal" is equivalent to the level of mRNA expression observed in the normal brain tissue.
* No p-value could be calculated because neither group showed a moderate or abundant increase in mRNA expression (see Table 1).
† P < 0.05 by Fisher's exact testLoh et al. BMC Cancer 2010, 10:268
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t e i n s ,  a n d  t h u s  b e  m o s t  r e l i a b l e  a s  m a r k e r s  f o r  f u t u r e
development of diagnostic tests or therapeutic interven-
tions. Of the 34 gliomas, we found that elevated Aurora A
and γ-tubulin mRNAs were significantly associated with
all high-grade gliomas all of which displayed mitotic dys-
regulation. Thus, regardless of the underlying mechanism
by which each glioma acquired altered mitotic regulation,
they all had elevated Aurora A and γ-tubulin. In the more
stringent two-level statistical test, Aurora A expression
alone was a significant predictor of the glioma grade.
Considering that γ-tubulin levels are likely a downstream
effect of Aurora A dysregulation, the lack of a significant
result in the two-level test does not make changes in γ-
tubulin completely irrelevant.
Aurora A, which is also known as serine/threonine
kinase 15 (STK15), is a key regulatory protein controlling
centrosome maturation, spindle assembly, and chromo-
some segregation [29]. An Aurora A gene mutation is
characterized by a centrosome separation defect [30]. In
addition, mutations in the Increase for Ploidy 1(Ipl1) gene
in Saccharomyces cerevisiae, that is closely homologous
to Aurora A, resulted in chromosome segregation defects
[31]. Furthermore, overexpression of Aurora A induced
centrosome amplification, aneuploidy, and transforma-
tion [32]. Human Aurora-related kinases were indeed
overexpressed in several human cancer types [33].
Although the effects of Aurora A overexpression and
gene mutation have been well-characterized in many can-
cers, its influence on cancer progression and therefore
grade are not as clear. Klein et al. [12] performed a similar
study of Aurora A mRNA expression in a panel of low-
and high-grade glioma samples and showed that, how-
ever, STK15/Aurora A was overexpressed in 60% of the
tumors analyzed, it was not predictive of glioma grade,
which is inconsistent with our data.
Although the sample size of this study is a necessary
limitation due to the difficulty in obtaining these samples,
analysis of human tissue rather than a cell line is more
clinically meaningful. In addition, this study supports
future exploration of these potential markers in more
extensive samplings as well as in other model systems.
For example, GBM8401 cells may provide a useful tool to
study the effects of altered Aurora A and γ-tubulin levels
on supernumerary centrosomes, aneuploidy, or cellular
transformation.
Conclusions
γ-tubulin and Aurora A mRNA levels were significantly
higher in high- versus low-grade gliomas. Markers for
mitotic dysregulation, such as supernumerary cen-
trosomes and altered centrosome-related mRNA and
protein expression, were observed in gliomas as com-
pared to normal tissue. Elevated mitotic regulatory pro-
teins, such as Aurora A, and altered levels of centrosome
structural proteins are common in many cancers, and
treatments may soon be developed which act on these
classes of proteins [3,4,29]. These results are clinically
useful for glioma staging as well as the development of
novel treatment strategies.
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